Navigation Links
BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference

common cold and some other respiratory infections, seasonal flu can cause severe illness, resulting in life-threatening complications. According to the Centers for Disease Control and Prevention, every year in the United States more than 200,000 people are hospitalized from flu complications, and about 36,000 people die from flu. Most at risk are young children, the elderly, and people with seriously compromised immune systems.

Avian influenza A viruses of H5N1 subtype are circulating among birds worldwide, the virus is considered extremely contagious in fowl. It is believed that all species of birds are susceptible to avian influenza, but domestic poultry, including chickens and turkeys, are among the more susceptible to the highly pathogenic strain. According to the World Health Organization, at least 261 people have contracted H5N1 avian influenza, of which at least 157 have died. Almost all of these infections are believed to have resulted from contact with infected poultry.

About BioCryst

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine(TM) in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life- threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine(TM) in markets across Europe, Asia, Australia and certain neighboring countries. In January, 2007 the U.S. Department of Health and Human Services (DHHS) awarded a $102.6 million, four-year contract to BioCryst for advanced development of peramivir to treat seasonal and life-threatening influenza. In Februar
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... for the fourth quarter of 2013 on Monday, February 3, ... release after the close of trading. (Logo: ... call to discuss the operating highlights and financial results for ...
(Date:1/14/2014)... The Brandeis Medical Center, led by Dr. Emmanuel Brandeis ... affordable laser tattoo removal experience with the advanced Astanza Duality laser ... high quality cosmetic services with cutting edge medical technology and offering ... California has seen a dramatic increase in the presence ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... treating MCLs nonsurgically, study findsROSEMONT, Ill., March 2 ... (MCL) may be treated successfully without surgery, according to ... of The Journal of the American Academy of ... review,s authors found, is properly diagnosing and understanding the ...
... Md., March 2 TissueGene, Inc. announced today that ... (KLS) has received regulatory allowance from the Korea Food ... clinical trial of TissueGene-C (TG-C) in patients with severe ... for the localized delivery of allogeneic human cells expressing ...
Cached Medicine Technology:Treating Knee Ligament Injuries 2Treating Knee Ligament Injuries 3TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee 2
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
(Date:4/24/2014)... the influenza pH1N1 virus caused the first flu pandemic ... May 2009 and killed more than 50 people in ... mainly during flu epidemics (winter/spring seasons). , Infections ... complicated illnesses. World Health Organization has recommended Tamiflu for ... disadvantage of this drug is that it targets viral ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... report that rats exposed to high-energy particles, simulating conditions ... show lapses in attention and slower reaction times, even ... ranges. , The cognitive impairments which affected a ... appear to be linked to protein changes in ... to hold true in humans, suggest it may be ...
(Date:4/23/2014)... whose testosterone falls below normal levels are more likely ... have heart disease and type 2 diabetes. A new ... further testing and possible treatment is described in an ... peer-reviewed publication from Mary Ann Liebert, Inc., publishers. The ... Men,s Health website at http://www.liebertpub.com/jmh . ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... cabinet, may help in easing out prostate problem, according to ... known to help in the prevention of arthritic inflammations, heart ... The researchers say that now it may help solve some ... enlarged prostates. ,It may help reduce the urinary ...
... view of The Sterling Council, of levying ?1 a week for ... refuses to buy. The complainant, Mrs. C, has not minced words ... the society, and truly a mockery of the free care provided ... emergency care system in her home in 2002. This allowed emergency ...
... of the University of Sao Paulo Medical School in Brazil ... getting the best care in case of chronic coronary artery ... to be published in the September edition of the Journal ... to receive their physician-recommended treatment showed a significantly lower incidence ...
... A British tourist in Hong Kong is suspected of having the ... been named and was admitted to a Hog Kong hospital// after ... man came to the country on April 4 and was admitted ... Chinese origin and underwent intestinal surgery earlier. Hong Kong health department ...
... A $500,000 television and radio ad campaign blaming GOP ... prescription drug program has been launched by the// Association ... ,The ad campaign accusing the lawmakers for blocking provisions ... companies for the best prescription cost has been targeted ...
... techniques and concussions among high school athletes found that ... of// concussion. ,In the current ... Medicine in Philadelphia and co-author Dr. Tracey Covassin of ... directors of athletics from Pennsylvania and New Jersey high ...
Cached Medicine News:Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 3Health News:Ad Campaign Targeting Republicans On Medicare Prescription Drug Program 2Health News:Proper Fitting Of Football Helmets Essential To Prevent Concussion 2
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures....
The Shandon Linistain GLX Linear Stainer is an economical mid-size linear stainer featuring 28 staining stations and a heater/dryer with fume control by a charcoal filter....
... Finesse E+ is a precision ... specimen advance with manual cutting. ... is easy to operate. Coarse ... the option of manually advancing ...
Medicine Products: